Technical Analysis for NBY - NovaBay Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 0.75 4.75% 0.03
NBY closed up 4.75 percent on Friday, November 1, 2024, on 3 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
MACD Bullish Centerline Cross Bullish 4.75%
Stochastic Reached Overbought Strength 4.75%
Wide Bands Range Expansion 4.75%

   Recent Intraday Alerts

Alert Time
Gap Up Closed about 21 hours ago
Gap Up Partially Closed about 21 hours ago
Down 3% about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
Down 2 % about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NovaBay Pharmaceuticals, Inc. Description

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It has categories of compounds, Aganocides and NeutroPhase. The company's Aganocide compounds comprise NVC-422 that is in Phase IIb clinical study for the treatment of adenoviral conjunctivitis, a contagious viral eye infection; impetigo, a highly contagious skin infection; and urinary catheter blockage and encrustation, and associated urinary tract infections. Its NeutroPhase product is a hypochlorous acid solution, has approved for the treatment of patients who suffer from chronic non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. The company has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. It also has strategic marketing agreement with Pioneer Pharma Co., Ltd. to market its pharmaceutical products in China and other Asian markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Acid Eye Pharmaceutical Products Catheter Ophthalmology Urology Dermatology Wound Ulcer Healing Acne Urinary Tract Infection Urinary Tract Infections Viral Conjunctivitis

Is NBY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.8415
52 Week Low 0.3611
Average Volume 3,520,845
200-Day Moving Average 2.69
50-Day Moving Average 0.60
20-Day Moving Average 0.63
10-Day Moving Average 0.63
Average True Range 0.07
RSI (14) 62.55
ADX 23.89
+DI 29.25
-DI 15.86
Chandelier Exit (Long, 3 ATRs) 0.56
Chandelier Exit (Short, 3 ATRs) 0.74
Upper Bollinger Bands 0.75
Lower Bollinger Band 0.52
Percent B (%b) 1.0
BandWidth 36.90
MACD Line 0.01
MACD Signal Line -0.01
MACD Histogram 0.0174
Fundamentals Value
Market Cap 4.9 Million
Num Shares 6.53 Million
EPS -7.05
Price-to-Earnings (P/E) Ratio -0.11
Price-to-Sales 0.07
Price-to-Book 0.20
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.85
Resistance 3 (R3) 0.84 0.79 0.83
Resistance 2 (R2) 0.79 0.77 0.80 0.83
Resistance 1 (R1) 0.77 0.75 0.78 0.78 0.82
Pivot Point 0.73 0.73 0.73 0.73 0.73
Support 1 (S1) 0.71 0.70 0.72 0.72 0.68
Support 2 (S2) 0.66 0.69 0.67 0.67
Support 3 (S3) 0.64 0.66 0.67
Support 4 (S4) 0.65